Longeveron, Inc. (LGVN)
2.49
-0.22
(-8.12%)
USD |
NASDAQ |
Sep 18, 16:00
2.49
0.00 (0.00%)
After-Hours: 20:00
Longeveron Enterprise Value : -1.598M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | -1.598M |
| September 17, 2026 | -0.9002M |
| September 16, 2026 | 11.69M |
| September 15, 2026 | 12.26M |
| September 14, 2026 | 12.45M |
| September 11, 2026 | 13.75M |
| September 10, 2026 | 11.57M |
| September 09, 2026 | 11.38M |
| September 08, 2026 | 11.60M |
| September 04, 2026 | 12.10M |
| September 03, 2026 | 11.38M |
| September 02, 2026 | 12.01M |
| September 01, 2026 | 11.91M |
| August 31, 2026 | 12.39M |
| August 28, 2026 | 11.82M |
| August 27, 2026 | 12.07M |
| August 26, 2026 | 12.81M |
| August 25, 2026 | 12.07M |
| August 24, 2026 | 17.08M |
| August 21, 2026 | 17.30M |
| August 20, 2026 | 16.77M |
| August 19, 2026 | 16.59M |
| August 18, 2026 | 15.47M |
| August 17, 2026 | 16.51M |
| August 14, 2026 | 13.97M |
| Date | Value |
|---|---|
| August 13, 2026 | 12.63M |
| August 12, 2026 | 14.19M |
| August 11, 2026 | 12.46M |
| August 10, 2026 | 13.86M |
| August 07, 2026 | 14.80M |
| August 06, 2026 | 15.04M |
| August 05, 2026 | 13.57M |
| August 04, 2026 | 14.04M |
| August 03, 2026 | 13.72M |
| July 31, 2026 | 12.75M |
| July 30, 2026 | 11.92M |
| July 29, 2026 | 9.377M |
| July 28, 2026 | 9.577M |
| July 27, 2026 | 9.878M |
| July 24, 2026 | 9.535M |
| July 23, 2026 | 9.764M |
| July 22, 2026 | 10.38M |
| July 21, 2026 | 9.903M |
| July 20, 2026 | 9.605M |
| July 17, 2026 | 10.23M |
| July 16, 2026 | 9.960M |
| July 15, 2026 | 10.66M |
| July 14, 2026 | 10.24M |
| July 13, 2026 | 10.52M |
| July 10, 2026 | 11.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.073M |
| Revenue (Quarterly) | 0.287M |
| Total Expenses (Quarterly) | 6.36M |
| EPS Diluted (Quarterly) | -1.936 |
| Gross Profit Margin (Quarterly) | -13.59% |
| Profit Margin (Quarterly) | -2.12K% |
| Earnings Yield | -407.7% |
| Normalized Earnings Yield | -407.65 |